CA2927977C - Tumoricidal and antimicrobial compositions and methods - Google Patents

Tumoricidal and antimicrobial compositions and methods Download PDF

Info

Publication number
CA2927977C
CA2927977C CA2927977A CA2927977A CA2927977C CA 2927977 C CA2927977 C CA 2927977C CA 2927977 A CA2927977 A CA 2927977A CA 2927977 A CA2927977 A CA 2927977A CA 2927977 C CA2927977 C CA 2927977C
Authority
CA
Canada
Prior art keywords
composition
cells
pharmaceutical composition
infection
exosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2927977A
Other languages
English (en)
French (fr)
Other versions
CA2927977A1 (en
Inventor
Hans G. KLINGEMANN
Barry J. SIMON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
Immunitybio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc filed Critical Immunitybio Inc
Publication of CA2927977A1 publication Critical patent/CA2927977A1/en
Application granted granted Critical
Publication of CA2927977C publication Critical patent/CA2927977C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2927977A 2013-11-01 2014-10-28 Tumoricidal and antimicrobial compositions and methods Active CA2927977C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899066P 2013-11-01 2013-11-01
US61/899,066 2013-11-01
PCT/US2014/062695 WO2015066054A1 (en) 2013-11-01 2014-10-28 Tumoricidal and antimicrobial compositions and methods

Publications (2)

Publication Number Publication Date
CA2927977A1 CA2927977A1 (en) 2015-05-07
CA2927977C true CA2927977C (en) 2024-03-05

Family

ID=53005034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2927977A Active CA2927977C (en) 2013-11-01 2014-10-28 Tumoricidal and antimicrobial compositions and methods

Country Status (9)

Country Link
US (10) US10258649B2 (cg-RX-API-DMAC7.html)
EP (3) EP3062800B1 (cg-RX-API-DMAC7.html)
JP (2) JP6603216B2 (cg-RX-API-DMAC7.html)
KR (5) KR20220147705A (cg-RX-API-DMAC7.html)
CN (2) CN105848662A (cg-RX-API-DMAC7.html)
AU (1) AU2014342477B2 (cg-RX-API-DMAC7.html)
CA (1) CA2927977C (cg-RX-API-DMAC7.html)
ES (1) ES2935906T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015066054A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2927977C (en) 2013-11-01 2024-03-05 Nantkwest, Inc. Tumoricidal and antimicrobial compositions and methods
CN107709552B (zh) * 2015-06-10 2022-05-13 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
WO2017100709A1 (en) * 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
WO2018015895A1 (en) * 2016-07-19 2018-01-25 National Institute Of Plant Genome Research Novel protein against fungal pathogens
EP3519562A4 (en) * 2016-09-29 2020-03-25 Nantkwest, Inc. NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
CN108324735B (zh) * 2017-01-20 2024-02-09 李莉 用于疾病治疗的胞外体制剂及其应用
WO2018208702A1 (en) * 2017-05-09 2018-11-15 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
US20210040451A1 (en) * 2018-01-31 2021-02-11 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
WO2021028787A1 (en) * 2019-08-12 2021-02-18 Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. Immune composition comprising respiratory syncytial virus (rsv) g polypeptide
WO2025221993A1 (en) 2024-04-18 2025-10-23 Immunitybio, Inc. Compositions and methods for producing il-16

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
WO1998049268A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
JP2007522161A (ja) 2004-02-13 2007-08-09 コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ カスタネア・サチバの葉抽出物を含有する化粧品組成物
EP1781777A1 (en) 2004-07-02 2007-05-09 Avaris AB Method for the genetic activation of cells and uses of said cells
DK3406631T3 (da) 2004-07-10 2022-08-29 The Institute For Cancer Res Genetisk modificerede humane naturlige dræbercellelinjer
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
HUE026536T2 (en) * 2008-02-22 2016-06-28 Agency For Science Tech And Res (A Star) Mesenchymal stem cell particles
US9347942B2 (en) * 2010-07-28 2016-05-24 Canvax Biotech Sl Ultrasensitive cell based sensors and uses thereof
KR101298012B1 (ko) 2011-02-08 2013-08-26 (주)차바이오앤디오스텍 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물
US20150212064A1 (en) * 2011-08-12 2015-07-30 The Childrens's Hospital Of Philadelphia Degranulation indicator and methods of use thereof
CA2927977C (en) 2013-11-01 2024-03-05 Nantkwest, Inc. Tumoricidal and antimicrobial compositions and methods
EP3641790A1 (en) 2017-06-20 2020-04-29 Nantkwest, Inc. Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
US20200306302A1 (en) 2017-08-04 2020-10-01 Nantkwest, Inc. Treating and inhibiting leukemia with nk-92 cells

Also Published As

Publication number Publication date
US20160250256A1 (en) 2016-09-01
US20190192568A1 (en) 2019-06-27
KR20160068976A (ko) 2016-06-15
KR20230085215A (ko) 2023-06-13
US11304977B2 (en) 2022-04-19
EP3062800A4 (en) 2017-04-19
WO2015066054A1 (en) 2015-05-07
US11975027B2 (en) 2024-05-07
US11213547B2 (en) 2022-01-04
US20190125801A1 (en) 2019-05-02
US20250170181A1 (en) 2025-05-29
ES2935906T3 (es) 2023-03-13
EP3062800B1 (en) 2020-04-08
CN105848662A (zh) 2016-08-10
JP2016539105A (ja) 2016-12-15
CA2927977A1 (en) 2015-05-07
US20240366674A1 (en) 2024-11-07
EP3701957B1 (en) 2022-12-28
EP3701957A1 (en) 2020-09-02
US10258649B2 (en) 2019-04-16
US20220160768A1 (en) 2022-05-26
US12064450B2 (en) 2024-08-20
KR102329796B1 (ko) 2021-11-23
US10772912B2 (en) 2020-09-15
US10517895B2 (en) 2019-12-31
US20190192570A1 (en) 2019-06-27
KR102476640B1 (ko) 2022-12-09
KR20210144920A (ko) 2021-11-30
US20200038445A1 (en) 2020-02-06
EP3062800A1 (en) 2016-09-07
US20190192569A1 (en) 2019-06-27
JP6603216B2 (ja) 2019-11-06
US10646516B2 (en) 2020-05-12
KR20250099421A (ko) 2025-07-01
US20220175838A1 (en) 2022-06-09
CN120501764A (zh) 2025-08-19
AU2014342477A1 (en) 2016-05-26
JP6870053B2 (ja) 2021-05-12
KR20220147705A (ko) 2022-11-03
JP2020073478A (ja) 2020-05-14
EP4134085A1 (en) 2023-02-15
AU2014342477B2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
US12064450B2 (en) Tumoricidal and antimicrobial compositions and methods
Dudek et al. Inducers of immunogenic cancer cell death
Fang et al. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei
HK1228299B (en) Tumoricidal compositions
HK1228299A1 (en) Tumoricidal compositions
US10004698B2 (en) Fibrin wafer/disc as a biological carrier for sustained delivery of curcumin
EP3197461A1 (en) New immunostimulatory compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022

EEER Examination request

Effective date: 20191022